Abstract

Long-Term Safety Profile of Biologic Therapies in Rheumatoid Arthritis

Author(s): Ahmad Nabil Youssef*

Biologic therapies have transformed the treatment landscape for rheumatoid arthritis (RA), providing targeted interventions that significantly improve clinical outcomes. However, their long-term safety profile remains a crucial consideration for clinicians and patients alike. This article reviews the available evidence on the long-term safety of various biologic agents used in RA, focusing on the risk of infections, malignancies, cardiovascular events, and other adverse effects. While biologics are generally well-tolerated, ongoing surveillance and research are essential to address potential risks and optimize patient safety. This review emphasizes the need for personalized treatment strategies that weigh the benefits of biologics against their long-term safety concerns.